94 related articles for article (PubMed ID: 8629053)
1. Prophylactic treatment for hemophilia A patients: a pilot study.
Chuansumrit A; Isarangkura P; Hathirat P
Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):243-6. PubMed ID: 8629053
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
4. Lyophilized cryoprecipitate for children with hemophilia A.
Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic replacement therapy in hemophilia. A case report (author's transl)].
Mitterstieler G
Padiatr Padol; 1976; 11(2-2):469-74. PubMed ID: 967509
[TBL] [Abstract][Full Text] [Related]
6. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
9. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic infusion regimens in the management of hemophilia.
Ljung RC
Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic transfusion for hypertrophic synovitis in children with hemophilia.
Greene WB; McMillan CW; Warren MW
Clin Orthop Relat Res; 1997 Oct; (343):19-24. PubMed ID: 9345200
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
14. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
15. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness in establishing hemophilia carrier detection and prenatal diagnosis services in a developing country with limited health resources.
Sasanakul W; Chuansumrit A; Ajjimakorn S; Krasaesub S; Sirachainan N; Chotsupakarn S; Kadegasem P; Rurgkhum S
Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):891-8. PubMed ID: 15115107
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
18. Advances in care of children with hemophilia.
Manco-Johnson MJ; Riske B; Kasper CK
Semin Thromb Hemost; 2003 Dec; 29(6):585-94. PubMed ID: 14719175
[TBL] [Abstract][Full Text] [Related]
19. Exchange transfusion and pulse steroid therapy in a hemophiliac with inhibitor.
Chuansumrit A; Isarangkura P; Krutvecho T; Hathirat P; Pintadit P
J Med Assoc Thai; 1989 Jan; 72 Suppl 1():139-43. PubMed ID: 2499649
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
Brühl P; Weibbach L; Brackmann HH
MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
